Wounds - Pipeline Review, H1 2012

Global Markets Direct, April 2012, Pages: 122

Wounds – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Wounds - Pipeline Review, H1 2012', provides an overview of the Wounds therapeutic pipeline. This report provides information on the therapeutic development for Wounds, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Wounds. 'Wounds - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Wounds.
- A review of the Wounds products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Wounds pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Wounds.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Wounds pipeline depth and focus of Wounds therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Wounds Therapeutic Products under Development, Key Players in Wounds Therapeutics, Wounds Pipeline Overview, Wounds Pipeline, Wounds Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Wounds Overview
Therapeutics Development
An Overview of Pipeline Products for Wounds
Wounds Therapeutics under Development by Companies
Wounds Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Wounds Therapeutics – Products under Development by Companies
Wounds Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Wounds Therapeutics Development
Sanofi-Aventis
Biotec Pharmacon ASA
CardioVascular BioTherapeutics, Inc.
Nanotherapeutics, Inc.
NexMed, Inc.
Bio3 Research S.r.l
Renovo Group Plc
CytoTools AG
AnaMar Medical AB
Foamix Ltd.
Garnet BioTherapeutics
Akebia Therapeutics, Inc.
Glycotex, Inc.
Phage Biotechnology Corporation
AndroScience Corporation
NovaLead Pharma Pvt. Ltd.
BRIDGE BIORESEARCH PLC
ImmuneRegen BioSciences, Inc.
CoDa Therapeutics, Inc.
Innocoll, Inc.
Beech Tree Labs, Inc.
Wounds – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Juvidex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CVBT-141B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Homspera - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NanoDOX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CTR-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vitaros - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GLYC-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GLYC-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASC-J9 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PXL01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DermaPro CI 05 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FGF-1 141 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GBT009 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Platelet Gel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Platelet Gel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Soluble Beta Glucan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nexagon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FXFM244 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DAC N-055 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cogenzia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Doxycycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rhPDGF-BB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ColMod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adalimumab1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Platelet Rich Plasma + Keratinocyte suspension - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lidocaine + Epinephrine + Tetracaine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cultured Autologous Keratinocytes - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Betadine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RNS60 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KUR-212 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RayVa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vasculotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antimicrobial Peptide LL-37 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AKB-4924 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BBR-012 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HO/07/09 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HO/03/06 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neurotensin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bactericidal Venom-Based Polypeptides - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Botox - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Wounds Therapeutics – Drug Profile Updates
Wounds Therapeutics – Discontinued Products
Wounds Therapeutics - Dormant Products
Wounds – Product Development Milestones
Featured News & Press Releases
Jan 19, 2012: Bridge BioResearch Receives Approval For Phase IIa Trial Protocol Of Isoniazide
Jan 09, 2012: NovaBay Pharmaceuticals Announces Strategic Marketing Agreement For NeutroPhase In China
Mar 18, 2011: National In Association With Globe Labs To Enter Into Discussion On Clinical Trials Protocols For GLB333
Mar 11, 2011: National Pharmaceuticals's GLB333 Receives Financial Grant
Feb 14, 2011: Pergamum To Extend Phase II Clinical Trial For Prevention Of Post-Surgical Adhesions
Jan 21, 2011: Biotec Pharmacon Receives Promising Interim Results From Animal Study
Nov 23, 2010: Phase IIa Completed For Dermapro With Excellent Safety Profile And Very Good Tolerance
Apr 12, 2010: PharmaSurgics To Extend Phase II Clinical Trial For Prevention Of Post-Surgical Adhesions
Dec 04, 2009: Pharmasurgics To Begin Phase II Clinical Trial For Prevention Of Post-Surgical Adhesions
Jul 14, 2009: PXL01 For The Treatment Of Post-Surgical Adhesion Formation Completes Phase I Clinical Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Wounds, H1 2012
Products under Development for Wounds – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Sanofi-Aventis, H1 2012
Biotec Pharmacon ASA, H1 2012
CardioVascular BioTherapeutics, Inc., H1 2012
Nanotherapeutics, Inc., H1 2012
NexMed, Inc., H1 2012
Bio3 Research S.r.l, H1 2012
Renovo Group Plc, H1 2012
CytoTools AG, H1 2012
AnaMar Medical AB, H1 2012
Foamix Ltd., H1 2012
Garnet BioTherapeutics, H1 2012
Akebia Therapeutics, Inc., H1 2012
Glycotex, Inc., H1 2012
Phage Biotechnology Corporation, H1 2012
AndroScience Corporation, H1 2012
NovaLead Pharma Pvt. Ltd., H1 2012
BRIDGE BIORESEARCH PLC, H1 2012
ImmuneRegen BioSciences, Inc., H1 2012
CoDa Therapeutics, Inc., H1 2012
Innocoll, Inc., H1 2012
Beech Tree Labs, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Wounds Therapeutics – Drug Profile Updates
Wounds Therapeutics – Discontinued Products
Wounds Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Wounds, H1 2012
Products under Development for Wounds – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Drug Addiction – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Liver Transplantation – Pipeline Review, H1 2013
• Skin And Skin Structure Infections (SSSI) – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013